
    
      A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical
      Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an
      add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to
      Current Therapy
    
  